Citigroup
QTTB icon

Citigroup’s Q32 Bio QTTB Stock Holding History

Citigroup’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.8K Buy
+2,888
New +$24.1K ﹤0.01% 5050
2025
Q4 		– Sell
-236
Closed -$467 – 6554
2025
Q3 		$467 Sell
236
-1,586
-87% -$3.05K ﹤0.01% 5715
2025
Q2 		$2.71K Sell
1,822
-2,580
-59% -$4.4K ﹤0.01% 5337
2025
Q1 		$7.26K Sell
4,402
-295
-6% -$794 ﹤0.01% 5239
2024
Q4 		$16.2K Buy
4,697
+306
+7% +$9.66K ﹤0.01% 5300
2024
Q3 		$196K Buy
4,391
+3,037
+224% +$112K ﹤0.01% 4356
2024
Q2 		$24.3K Buy
+1,354
New +$32.4K ﹤0.01% 4941
2023
Q1 		– Sell
-3,445
Closed -$78.1K – 5921
2022
Q4 		$78.1K Sell
3,445
-1,474
-30% -$39.1K ﹤0.01% 4117
2022
Q3 		$143K Sell
4,919
-7,312
-60% -$298K ﹤0.01% 3932
2022
Q2 		$434K Buy
12,231
+11,996
+5,105% +$410K ﹤0.01% 3337
2022
Q1 		$13K Sell
235
-492
-68% -$30.6K ﹤0.01% 5406
2021
Q4 		$48K Buy
727
+262
+56% +$25.4K ﹤0.01% 5093
2021
Q3 		$66K Buy
465
+96
+26% +$12.2K ﹤0.01% 4597
2021
Q2 		$48K Sell
369
-1,184
-76% -$148K ﹤0.01% 4852
2021
Q1 		$263K Buy
1,553
+126
+9% +$26.5K ﹤0.01% 3860
2020
Q4 		$290K Buy
1,427
+994
+230% +$192K ﹤0.01% 4696
2020
Q3 		$83K Sell
433
-2,307
-84% -$517K ﹤0.01% 5258
2020
Q2 		$749K Buy
2,740
+1,513
+123% +$403K ﹤0.01% 3855
2020
Q1 		$344K Buy
1,227
+637
+108% +$195K ﹤0.01% 4221
2019
Q4 		$220K Sell
590
-1,421
-71% -$407K ﹤0.01% 5108
2019
Q3 		$655K Sell
2,011
-597
-23% -$203K ﹤0.01% 4086
2019
Q2 		$918K Buy
2,608
+2,327
+828% +$914K ﹤0.01% 3733
2019
Q1 		$140K Buy
281
+49
+21% +$21.9K ﹤0.01% 5439
2018
Q4 		$93K Buy
232
+80
+53% +$30.3K ﹤0.01% 5714
2018
Q3 		$62K Buy
152
+76
+100% +$25.8K ﹤0.01% 6346
2018
Q2 		$28K Buy
+76
New +$27.2K ﹤0.01% 6752

Other funds holding QTTB

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citigroup's QTTB Position: Q2 2026 in Review

Citigroup opened a new position in Q32 Bio (QTTB) in Q2 2026: 2,888 shares worth $36.8K. The stake represents ﹤0.01% of the portfolio and ranks #5050 among its holdings. This is a return to the name: Citigroup previously reported a position in QTTB as recently as Q3 2025.

Citigroup first reported a position in QTTB in Q2 2018 and has held it in 26 quarters since. The position peaked at $918K in Q2 2019. 72 funds tracked by Wall St. Rank hold QTTB as of Q2 2026.

  • Citigroup held 2,888 shares of Q32 Bio worth $36.8K as of Q2 2026.
  • Q32 Bio was a new Citigroup position in Q2 2026.
  • Q32 Bio made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5050 holding.
  • Citigroup first reported a position in Q32 Bio in Q2 2018 and has held it in 26 quarters since.
  • Citigroup's Q32 Bio position peaked at $918K in Q2 2019.
  • 72 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.